Regardless of who controls Congress after the midterms, continued pressure to lower drug prices could weigh on biotech investment, licensing and M&A.
The big picture: As health care costs continue to rise faster than inflation and many Americans report difficulty paying for prescriptions, drug affordability has become a powerful bipartisan issue.